Phynova Group PLC (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, announces in accordance with AIM Rule 20 that it has today posted a newsletter to its Shareholders.
For further information, please contact:
Phynova Group PLC
07775 920 963
Robert Miller, Chief Executive Officer
www.phynova.com
Nominated Adviser:
Nabarro Wells & Co. Limited
020 7710 7400
Marc Cramsie/John Wilkes
Broker:
J M Finn & Co. Limited
020 7628 9688
Sam Smith
Media enquiries:
Abchurch Communications
020 7398 7700
Peter Laing/Ashley Tapp/Stephanie Cuthbert
Stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com
END